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Background: The role of IGF binding protein 2 (IGFBP2) in cancer development is intriguing. Previously we
identified IGFBP2 as an extrinsic factor that supports the activity of hematopoietic stem cells (HSCs).
Methods and results: Here we investigated the role of IGFBP2 in in human leukemia cells and in the retroviral
AML1-ETO9a transplantation acute myeloid leukemia (AML) mouse model.
Results: IGFBP2 is highly expressed in certain human AML and acute lymphoblastic leukemia (ALL) cells. Inhibition
of expression of endogenous IGFBP2 in human leukemia cells led to elevated apoptosis and decreased migration
and, consistently, to decreased activation of AKT and other signaling molecules. We also studied the effects of
IGFBP2 knockout in the retroviral AML1-ETO9a transplantation AML mouse model. The deletion of IGFBP2 in donor
AML cells significantly decreased leukemia development in transplanted mice. Lack of IGFBP2 resulted in
upregulation of PTEN expression and downregulation of AKT activation, in the mouse AML cells. The treatment of
IGFBP2 deficient AML cells with a PTEN inhibitor restored the wild-type colony forming ability. The deletion of
IGFBP2 also led to decreased AML infiltration into peripheral organs and tissues, suggesting that IGFBP2 is required
for the migration of AML cells out of bone marrow.
Conclusion: IGFBP2 is a critical cell-autonomous factor that promotes the survival and migration of acute leukemia cells.Introduction
Acute myeloid leukemia (AML) is characterized by rapid
proliferation of immature myeloid blasts in the bone
marrow. It is the most common acute leukemia affecting
adults and accounts for about 1.2% of cancer deaths in
the United States each year. Despite treatment, the ma-
jority of the patients relapse within 5 years [1]. To effect-
ively treat AML, new molecular targets and therapeutic
approaches need to be identified.
Insulin-like growth factor binding protein 2 (IGFBP2)
is a member of the IGFBP family; this family contains at
least six circulating proteins that bind IGF-1 and IGF-2
with an affinity equal or greater than that of the three
IGF receptors. IGFBPs modulate the biological effects
of IGFs by controlling IGF distribution, function, and* Correspondence: alec.zhang@utsouthwestern.edu
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reproduction in any medium, provided the oractivity [2,3]. IGFBP2 preferentially binds IGF-2 over
IGF-1. IGFBP2 is expressed in the fetus and in a num-
ber of adult tissues and biological fluids [4].
The role of IGFBP2 in cell growth and cancer develop-
ment is intriguing. While IGFBP2 can bind to IGF
ligands and displays IGF-dependent growth inhibitory
effects on many cell types, it also has intrinsic bioactiv-
ities that are independent of IGF-1 and IGF-2. IGFBP2
binds to the cell surface [5,6] and binds to integrin α5
[6-8] and to αv [9] extracellularly and intracellularly. It
stimulates telomerase activity [10], activates MMP-2 [11],
modulates MAPK activation [10], and supports prolifera-
tion, survival, differentiation, and motility of various types
of cells by suppression of PTEN and activation of AKT, in-
tegrin, integrin-linked kinase (ILK), and NF-κB pathways
[6-8,10,12-23]. Intracellular IGFBP2 promotes angiogen-
esis by stimulating VEGF transactivation [24]. In addition,
oxidative stress leads to the uptake of IGFBP2 into the cell
cytosol after 12–24 h [12,25].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 IGFBP2 is highly expressed in human acute myeloid
leukemia cells. (A) An in silico analysis of human IGFBP2 mRNA
expression in different human AML subtypes (n = 195, TCGA database;
* p < 0.05). (B) Expression of IGFBP2 in different human cancer cell lines
as determined by real-time RT-PCR (n = 3). * significant different from
other cell line values, p < 0.05.
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AML patients than in healthy volunteers [26]. A lower
IGFBP2 level is associated with longer-term survival of
patients with AML and ALL [27,28]. Expression of
IGFBP2 is also an independent factor for the prediction
of relapse of AML and ALL [26,27,29,30]. Moreover,
IGFBP2 is overexpressed in many patients with other tu-
mors, and in some cases its expression correlates with
grade of malignancy [6,10,12]. The level of IGFBP2 ap-
pears to be low in well-differentiated tumors but high in
poorly differentiated tumors [31].
We recently identified IGFBP2 as an extrinsic factor
that supports the activity of hematopoietic stem cells
(HSCs) [19,32,33]. To understand the potential func-
tional role of IGFBP2 in leukemia development, we
addressed several questions in the current study: 1) Is
IGFBP2 expressed by leukemia cells? If so, what is func-
tion for these cells? 2) Is IGFBP2’s effect on leukemia
cells an environmental effect or cell-autonomous effect?
3) What signaling pathways are regulated by IGFBP2 in
leukemia cells? We determined that IGFBP2 supports
the survival and migration of acute leukemia cells in a
cell-autonomous manner. IGFBP2 is essential for regula-
tion of several signaling pathways including PTEN/AKT
signaling in AML and perhaps B-ALL cells.
Results
IGFBP2 is highly expressed in certain human AML cells
We performed an in silico analysis of IGFBP2 mRNA ex-
pression in different subtypes of human AML based on
data from the TCGA AML database (http://cancergenome.
nih.gov/; accessed November 5, 2012). IGFBP2 is
expressed at significantly higher levels in cells of the M3
subtype than of other subtypes tested (Figure 1A). The
M3 subtype is characteristic of the acute promyelocytic
leukemia (APL) [t (15;17)] that generates the fusion
protein promyelocytic leukemia-retinoic acid receptor α
(PML-RARA).
We further measured IGFBP2 expression in a number
of human cancer cell lines including AML and ALL lines.
Although IGFBP2 mRNA was expressed at the highest
levels in the M3 subtype NB4 AML cells, it was also
highly expressed in some other AML and B cell-derived
ALL (B-ALL) cells including MV4-11 (M5 AML), U937
(B-ALL), and RCH-ACV (B-ALL) (Figure 1B). By contrast,
it was expressed at very low levels in K562 (CML) cells
and NALM-6 (B-ALL) cells (Figure 1B).
IGFBP2 is critical for survival and migration of human
AML cells
We studied the potential function of IGFBP2 in human
leukemia cells by silencing its expression with lentivirus
encoded small hairpin RNAs (shRNAs). Three previously
reported RNAi sequences targeting IGFBP2 mRNA [34]were evaluated; shRNA3 efficiently decreased expres-
sion of IGFBP2 mRNA (Figure 2A) and IGFBP2 protein
(Figure 2B), concordant with a previous report [35].
Importantly, the inhibition of IGFBP2 expression effect-
ively inhibited the in vitro growth of NB4, MV4-11,
U937, and RCHACV cells that express high endogenous
IGFBP2 levels (Figure 2C-D) but had little effect on
K562 cells or NAML-6 cells that have extremely low
levels of IGFBP2 expression (Figure 2E). The inclusion of
extrinsic recombinant IGFBP2 in the culture medium did
not rescue the defects in leukemia cells treated with
shRNA targeting IGFBP2 (Figure 2D). This result suggests
that leukemia cells behave differently from HSCs and
certain solid cancer cells. While IGFBP2 has cell-
autonomous effect to support growth of leukemia
cells, the extrinsic IGFBP2 stimulates the activity of
HSCs and some other cancer cells such as breast can-
cer cells [19,23,33].
To determine the underlying mechanism by which
IGFBP2 supports the growth of leukemia cells, we com-
pared levels of apoptosis and cell cycle status of AML
cells treated with shRNA3 or scrambled control shRNA.
Cells treated with the shRNA targeting IGFBP2 had in-
creased levels of early and late apoptosis compared to
cells treated with the control shRNA (Figure 2F; 0.60%,
Figure 2 (See legend on next page.)
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Figure 2 IGFBP2 is critical for survival and migration of human AML cells. (A) IGFBP2 mRNA expression was reduced in four human
leukemia cell lines by shRNA3 as determined by real-time RT-PCR (n = 3). * significant different from scramble control values, p < 0.05. (B) IGFBP2 levels
were reduced in four human leukemia cell lines by shRNA3 as determined by western blotting (n = 3). (C) Inhibition of IGFBP2 expression with shRNA3
in four human leukemia cell lines that have high IGFBP2 levels decreased cell growth in culture (n = 3). (D) Effects of inhibition of IGFBP2 expression
with shRNA3 cannot be rescued by extrinsic recombinant IGFBP2 protein (500 ng/ml) (n = 3). (E) Inhibition of IGFBP2 expression with shRNA3 in two
human leukemia cell lines that have low IGFBP2 levels did not decrease cell growth in culture (n = 3). (F) Inhibition of IGFBP2 expression with shRNA3
in four human leukemia cell lines that have high IGFBP2 levels induced apoptosis as determined by Annexin v and 7-AAD staining in flow cytometry.
(G) Inhibition of IGFBP2 expression with shRNA3 did not induce cell cycle arrest in AML cell lines as determined by propidium iodide staining and
analysis by flow cytometry. (H-I) Inhibition of IGFBP2 expression with shRNA3 suppressed NB4 and U937 cell migration. Indicated cells transduced with
scrambled shRNA or shRNA3 were placed in the upper chamber of a transwell insert (5-μm pore size). Cells were allowed to migrate for 3 or 12 hours
at 37°C before harvesting and analysis (n = 3; ** p < 0.01). The migration was normalized by the cell numbers at 12 hr. (J-L) Inhibition of IGFBP2
expression with shRNA3 decreased the activation of ERK and AKT in NB4, MV4-11, and U937 cell lines.
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vs. 0.65%, 4.09%, 2.35%, and 1.38% in knockdown cells,
and 0.93%, 1.92%, 1.94%, and 2.76% late apoptotic cells
in controls vs. 7.91%, 5.68%, 8.29%, and 8.51% in
knockdown cells, at day 6 of culture). In contrast, there
was no significant difference in cell cycle distribution
between cells treated with control shRNA and shRNA
targeting IGFBP2 (Figure 2G). Furthermore, we observed
that inhibition of IGFBP2 expression in NB4 or U937
cells decreased cell migration in a transwell assay
(Figure 2H-I).
We next examined whether ERK and AKT signaling
are involved in the effects of IGFBP2 on these leukemia
cells. Compared to control treated cells, NB4, MV4-11,
and U937 cells treated with shRNA targeting IGFBP2
had significantly decreased phosphorylation of ERK and
AKT (Figure 2J-L). We also observed increased levels of
PTEN in NB4 cells (Additional file 1: Figure S1). These
results suggest that, as observed in other systems
[6-8,10,12-22], ERK and PTEN/AKT signaling pathways
are possible effectors of IGFBP2 in human leukemia
cells. Together, our results suggest that IGFBP2 has cell-
autonomous effects on leukemia cells and is critical for
their survival and migration.
IGFBP2 supports leukemia development in the mouse
AML model
To gain a deeper understanding of the mechanism by
which IGFBP2 supports AML development, we studied
AML development in IGFBP2-null mice. While IGFBP2 is
expressed at high levels by M3 t(15:17) APL cells that pro-
duce a fusion protein promyelocytic leukemia-retinoic acid
receptor α (PML-RARA), the physiologic PML-RARA ex-
pression from the mouse pml locus rarely causes leukemia
development [36]. IGFBP2 is also highly expressed in
AML1-ETO cells (Additional file 1: Figure S2) [37], which
do cause leukemia development in a transplant model
[38]. We, therefore, sought to use IGFBP2-null mice to
study how IGFBP2 affects AML development in the
AML1-ETO9a (AE9a) retroviral transplantation mouse
model [38].In drastic contrast to the observation that normal
HSCs do not show a detectable IGFBP2 mRNA level
and differentiated hematopoietic cells express significant
amount of IGFBP2 [19], IGFBP2 is highly expressed in
both AML stem cells (AML-SC) enriched bone marrow
Lin-Kit+Sca-1- cells [38] and differentiated Lin-Kit-Sca-1-
cells in the AML1-ETO9a AML model (Figure 3A). The
mice transplanted with the AE9a-transduced IGFBP2-
null cells developed AML significantly more slowly than
controls transplanted with wild-type cells (Figure 3B).
All mice transplanted with control AE9a AML cells died
within 240 days post-transplantation. In contrast, more
than 80% of mice transplanted with IGFBP2-null coun-
terparts survived longer than 240 days (Figure 3B). The
percentages of wild-type GFP+ AML cells were signifi-
cantly greater than the null counterparts after 3 months
post-transplantation (Figure 3C). However, within the
GFP+ leukemia compartments, there were no significant
differences in the AML-SC population or in the more
differentiated Mac-1+, B220+, or CD3+ cells in mice that
received IGFBP2-null cells and in those transplanted
with wild-type cells based on flow cytometry analyses
(Figure 3D). Mice transplanted with IGFBP2-null AML
cells had significantly decreased liver and spleen sizes
than mice transplanted with wild-type cells at 4 months
post-transplantation (Figure 3E). The examination of
leukemia infiltration into spleen and liver also revealed
that IGFBP2-null AML cells less effectively induced
leukemia than wild-type AML cells (Figure 3F). The ana-
lysis of key signaling molecules revealed that deficiency
of IGFBP2 decreased the levels of phosphorylated forms
of AKT and STAT3 whereas those of ERK and STAT6
remained unaffected (Figure 3G). Colony forming unit
(CFU) assays showed that knockout of IGFBP2 led to a
20% decrease in CFUs in the primary plating, and more
than 30% of decrease in CFUs in the secondary plating
(Figure 3H), indicating that IGFBP2 enhances self-renewal
of AML cells in vitro. Deficiency of IGFBP2 also altered
the morphology of colonies (Figure 3H, upper panels).
We performed secondary transplantation to investigate
the role of IGFBP2 in the activity of mouse AML-SCs.
Figure 3 Inhibition of IGFBP2 expression delays leukemia development in the AML1-ETO transplantation mouse AML model.
(A) Expression of IGFBP2 in AML1-ETO infected BM Lin-Kit+Sca-1- cells and Lin-Kit-Sca-1- cells as determined by real-time RT-PCR (n = 3). (B) Mice
transplanted with AML1-ETO-infected wild-type hematopoietic progenitors had significantly reduced survival compared to that of mice
transplanted with AML1-ETO-infected IGFBP2-null hematopoietic progenitors (n = 14; p < 0.005). (C) IGFBP2-null AML mice had fewer leukemic GFP+
cells in peripheral blood than mice transplanted with wild-type cells at 3–4 months after transplantation (n = 14; * p < 0.05). (D) Percentages of
progenitors and differentiated cells in the control and IGFBP2-null leukemic GFP+ compartments of peripheral blood at four months after
transplantation (n = 14). (E) Comparison of the sizes of spleens and livers of the mice transplanted with wild-type AML1-ETO9a cells and those
transplanted with IGFBP2-null AML1-ETO9a cells at 4 month after transplantation (* p < 0.05). (F) Histological hematoxylin/eosin staining of AML
infiltration in the livers and spleens and Wright-Giemsa staining of peripheral blood cells of mice transplanted with control or IGFBP2-null AML1-ETO9a
cells. (G) Phosphorylation of AKT and STAT3 decreased in IGFBP2-null AML BM cells compared with the levels in control cells. (H) The IGFBP2-null AML
BM cells from primary transplant mice showed significantly decreased colony forming ability (n = 3) and morphology changes relative to cells from
mice transplanted with wild-type AML cells (n = 3, * p < 0.05).
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AML development during secondary transplantation
(Figure 4A-F) and had dramatically decreased AKT and
STAT3 activation (Figure 4G) as was observed in the
primary transplanted cells. IGFBP2-null cells resulted in
only 5% of the CFU of wild-type AML cells (Figure 4H).
Importantly, similar to the human leukemia cells, the de-
letion of IGFBP2 induced increased apoptosis of mouse
bone marrow AML cells (Figure 4I). In both primary
and secondary transplantation, PTEN levels were in-
creased in IGFBP2-null AML cells relative to levels in
wild-type cells (Figure 4J). Importantly, the PTEN inhibi-
tor bpV(HOpic) was capable of rescuing the CFU defects
of null bone marrow AML cells (Figure 4K). Therefore,
IGFBP2 supports the survival of AML-SCs, and PTEN/
AKT signaling and STAT3 signaling may play roles in
IGFBP2-regulated AML-SC activity.
IGFBP2 supports the mobilization of mouse AML cells
Because IGFBP2 plays a role in cell migration [7,11,12,20],
we compared the distribution of wild-type and IGFBP2-null AML cells in bone marrow and peripheral tissues and
organs. Although we found that the percentages of
IGFBP2-null AML cells did not differ from those of
wild-type cells in BM, the existence of IGFBP2-null
AML cells in peripheral blood, spleen, and liver was
significantly decreased relative to levels of wild-type
AML cells (Figure 5A-B). Concordantly, the expression
of surface proteins (CX3CR1, CXCR4, EMB, ITGB4,
LSP, VCAM1) important for leukemia infiltration was
downregulated in IGFBP2-null bone marrow AML cells
(Figure 5C). Together with the migration enhancing ef-
fect of IGFBP2 in human leukemia cells (Figure 2H-I), our
results suggest that IGFBP2 enhances the mobilization of
AML cells, thus accelerating AML development.
Discussion
Previously, we showed that IGFBP2 stimulates the activ-
ities of mouse and human HSCs in vitro and in vivo
[19,32,39]. Here, we demonstrated that, 1) IGFBP2 is
highly expressed by certain types of acute leukemia cells,
2) IGFBP2 is a cell-autonomous factor that promotes
Figure 4 (See legend on next page.)
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Figure 4 Knockout of IGFBP2 delays leukemia development in the AML1-ETO AML model upon serial transplantation. (A) Mice
transplanted with AML1-ETO-infected wild-type hematopoietic progenitors had significantly reduced survival upon secondary transplantation
compared to that of mice transplanted with IGFBP2-null cells (n = 11; p < 0.01). (B) IGFBP2-null AML mice had significantly fewer leukemic GFP+
cells in peripheral blood compared to mice transplanted with wild-type cells at 3 weeks after secondary transplantation (n = 11; * p <0.05).
(C) Percentages of progenitors and differentiated cells in the control and IGFBP2-null leukemic GFP+ compartments of peripheral blood at 3 weeks
after secondary transplantation (n = 10). (D) Comparison of the sizes of spleens and livers of the mice transplanted with wild-type and IGFBP2-null
AML1-ETO9a cells at 1 month after secondary transplantation (* p < 0.05). (E) Histological hematoxylin/eosin staining of AML infiltration in the livers
and spleens of mice secondarily transplanted with control or IGFBP2-null AML1-ETO9a cells. (F) Representative Wright-Giemsa staining of peripheral
blood and bone marrow AML cells from leukemic mice after secondary transplantation. (G) Phosphorylation of AKT and STAT3 decreased in IGFBP2-
null AML BM cells compared with levels in the control cells. (H) IGFBP2-null AML1-ETO9a BM cells from secondarily transplanted mice had dramatically
decreased CFU forming ability, including decreased colony number and size, relative to wild-type AML1-ETO9a BM cells (n = 6; * p < 0.05). (I) IGFBP2-
null AML1-ETO9a BM cells showed increased apoptosis relative to control cells (n = 6; * p < 0.05). (J) AML cells from IGFBP2-null BM showed higher
levels of PTEN expression than those from control mice both in primary and secondary transplantation. (K) A PTEN inhibitor increased the CFU activity
of IGFBP2-null AML cells (n = 3; * p < 0.05).
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both survival and migration of leukemia cells, and 4) the
stimulating effect of IGFBP2 on acute leukemia cells de-
pends on PTEN signaling. To our knowledge, this is the
first functional demonstration that IGFBP2 is critical for
leukemia development. Our results are concordant with
reports that IGFBP2 is considered a prognostic factor
for AML and ALL [26,27,29,30] and activates AKT [7]
and suppresses PTEN expression [22,23] in certain solid
cancer cells.
It is rather surprising that IGFBP2, a non-essential fac-
tor for normal development, is detrimental for acute
leukemia cells upon deletion. Our study suggests that
the different effects of IGFBP2 on normal HSCs andFigure 5 Knockout of IGFBP2 decreases migration of leukemia cells o
(A-B) Representative flow cytometry plots (A) and summary of results (B) sho
decreased GFP+ AML cells in peripheral blood, liver, and spleen but not in BM
IGFBP2-null AML BM cells have decreased expression of a number of surface pleukemia cells contribute to this phenomenon. Normal
HSCs express little IGFBP2 per se [19], whereas both
leukemia stem cells and differentiated leukemia cells
have similar high expression of IGFBP2. Consistently,
the extrinsic IGFBP2 has a supporting effect on HSC
expansion [19,33], and intrinsic IGFBP2 promotes the
survival and migration of AML cells (including both
AML–SCs and differentiated AML cells) in a cell-
autonomous manner. Inhibition of IGFBP2 expression in
human leukemia cell lines effectively inhibited growth of
these cells. Importantly, the exogenous recombinant
IGFBP2 added to the culture medium did not have a po-
tent rescue effect. In addition, HSCs and acute leukemia
cells represent different cell identities and likely haveut of bone marrow in the AML1-ETO mouse AML model.
wing the mice transplanted with IGFBP2-null AML cells have significantly
compared with the mice transplanted with control AML cells. (C) The
roteins compared to wild-type cells (n = 3; * p < 0.05).
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mechanisms to utilize IGFBP2. While a major question
in IGFBP biology is whether the effect of IGFBP2 is en-
vironmental or cell-autonomous, our studies on HSCs
and leukemia indicated that the answers are cell-type-
dependent.
The cell-autonomous effect of IGFBP2 in leukemia
cells is also different from the extrinsic effect of IGFBP2
in supporting survival of certain solid cancer cells such
as breast cancer cells [23]. Nevertheless, it has been
shown that intrinsic IGFBP2 interacts with integrin α5β1
and promotes migration of glioma cells and glioma pro-
gression through activation of AKT, ILK, and NF-κB
pathways [7,8,20]. Moreover, endogenous IGFBP2 stimu-
lates the transactivation of VEGF and supports angio-
genesis [24]. Concordantly, here our study suggested that
the AKT pathway in leukemia cells plays a critical role in
the effects of IGFBP2, and we demonstrated that the
PTEN inhibitor treatment rescues the colony forming ac-
tivity of the IGFBP2 deficient leukemia cells. Overall, the
diverse IGFBP2 actions possibly result from the different
cell identities that have distinctive extracellular or intracel-
lular IGFBP2-interacting molecules, and the IGFBP2 re-
lated signaling in different cells may be quite different.
Indeed, consistent with the different expression of IGFBP2
in HSCs and leukemia cells, the signaling defects we ob-
served in IGFBP2 deficient leukemia cells are more dra-
matic than in IGFBP2-null HSCs, and also are unique
compared to defects observed in other cancer cells upon
IGFBP2 deletion [23]. Further investigations are warranted
to determine how IGFBP2 has different effects on normal
cells and various types of cancer cells.
Conclusion
Here we showed that IGFBP2 was required for both of
survival and migration of AML and ALL cells. The inhib-
ition of IGFBP2 expression in human AML and B-ALL
cell lines increased apoptosis and decreased migration,
and these results were confirmed in vivo using the
IGFBP2-null AML1-ETO9a model. These novel data
indicated that IGFBP2 supports leukemia development
autonomously by both enhancing cell survival and pro-
moting migration out of bone marrow and infiltration into
peripheral organs and tissues. The ability of IGFBP2 to
support cancer cell survival or migration has been docu-
mented in other cancer cell types. For example, IGFBP2
has anti-apoptotic effects in multiple types of solid cancer
[7,12,13,23], binds to integrin α5 resulting in migration of
Ewing’s sarcoma cells [6], and activates integrin β1 to in-
duce glioma cell motility [20]. Because IGFBP2 is not
expressed by normal HSCs but highly expressed by
leukemia stem cells and differentiated leukemia cells, it is
desirable to develop anti-IGFBP2 therapy that may effect-
ively induce apoptosis and block mobilization of leukemiacells including leukemia stem cells with minimal toxicity
to normal HSCs.
Methods
Mice, shRNAs, and primers
C57BL/6 CD45.2 and CD45.1 mice were purchased from
the National Cancer Institute and the University of
Texas Southwestern Medical Center animal breeding
core facility. The IGFBP2+/− mice in C57BL/6 background
were previously described [19]. Mice were maintained at
the University of Texas Southwestern Medical Center
animal facility. All animal experiments were performed
with the approval of UT Southwestern Committee on
Animal Care. Western blots were performed to detect the
IGFBP2 protein using a goat anti-IGFBP2 antibody (SC-
6002; Santa Cruz Biotechnology). The sequences for the






Human IGFBP2 Forward Primer: 5′-GCCCTCTGGA
GCACCTCTACT-3′
Human IGFBP2 Reverse Primer: 5′-CATCTTGCAC
TGTTTGAGGTTGTAC-3′
Retroviral infection and transplantation
Human embryonic kidney 293 T cells were grown in
DMEM with 10% fetal bovine serum (FBS) and transfected
with an MSCV-AML1-ETO9a-IRES-GFP encoding plas-
mid [38] and pCL-ECO to produce retroviruses. The in-
fection of Lin- cells with retrovirus was performed as
described previously [40]. Briefly, we incubated Lin- cells
overnight in medium with 10% FBS, 20 ng/mL SCF, 20 ng/
ml IL-3, and 10 ng/mL IL-6, followed by spin infection
with retroviral supernatant in the presence of 4 μg/mL
polybrene. Infected cells (300,000) were transplanted
into lethally irradiated (1000 rad) C57BL/6 mice by
retro-orbital injection. For secondary transplantation, GFP+
bone marrow (BM) cells from primary transplanted mice
were transplanted into mice with 100,000 normal BM cells
as competitors.
Flow cytometry, immunohistochemistry, and cytospin
Flow cytometry, immunohistochemistry, and cytospin
were performed as we described previously [40]. For
flow cytometry analysis of AML cells, peripheral blood
or BM cells were stained with anti-Lineage-Biotin
(followed by streptavidin-APC), anti-Mac-1-APC, anti-
Gr-1-PE, anti-CD3-APC, anti-B220-PE, or anti-Kit-PE
monoclonal antibodies (BD Pharmingen). Cell cycle sta-
tus was determined by propidium iodide staining. For
analysis of apoptosis, cells were stained with PE-
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according to the manufacturer’s instructions.
Colony forming unit (CFU) assays
Cells from AML mice were plated in methylcellulose
(M3534, Stem Cell Technologies) for CFU-GM assays,
according to the manufacturer’s protocols and our previ-
ously published protocol [40,41]. After 7 days, 2000 cells
from three dishes were used for secondary replating. 1 μM
PTEN inhibitor bpV(HOpic) (CalBiochem) was used to
treat AML cells for the CFU assay as indicated.
Western blotting
Cell lysates (100 μg samples) were separated by electro-
phoresis on a 4-12% SDS-polyacrylamide gel, and the
proteins were electroblotted onto a nitrocellulose mem-
brane. The membrane was probed with primary anti-
body for 1 h at room temperature and then incubated
with horseradish peroxidase-conjugated secondary anti-
body, which was detected with the chemiluminescence
SuperSignal kit (Pierce).
Quantitative RT-PCR
Total RNA was isolated from FACS-collected cells. First-
strand cDNA was synthesized using SuperScript II RT
(Invitrogen). Samples were analyzed in triplicate 25-μl re-
actions (300 nM each primer, 12.5 μl of Master mix) as
adapted from the standard protocol provided in SYBR
Green PCR Master Mix and RT-PCR Protocols provided
by Applied Biosystems. Primers were purchased from
Qiagen or Sigma. The default PCR protocol was used on
an Applied Biosystems Prism 7000 Sequence Detection
System. The mRNA level in each population was normal-
ized to the level of β-actin RNA transcripts present in the
same sample as described previously [39].
Statistical analyses
Data are expressed as mean ± SEM. Data were analyzed
by Student’s t test and were considered statistically sig-
nificant if p < 0.05. The survival rates of the two groups
were analyzed using a log-rank test.
Additional file
Additional file 1: Figure S1. PTEN levels were increased in NB4 cells
treated with shRNA targeting IGFBP2. Figure S2. An in silico analysis of
IGFBP2 expression in AML1-ETO transduced CD34+ human cord blood or
peripheral blood cells based on the published database in reference 37.
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